RCTJadad 1/5RandomizedDouble-BlindPlacebo-Controlled

Can One Dose of Creatine Beat a Sleepless Night? What This New Trial Found

NutrientsApril 10, 2026Vol. 18 (8)

Summary

If you've ever pulled an all-nighter and reached for coffee to salvage your brain the next day, this new German trial offers an intriguing alternative — or complement: creatine. Published in Nutrients (April 2026), the study asked a sharp, practical question: does a single, "normal-sized" dose of creatine — not the mega-doses used in earlier research — still protect your thinking during sleep deprivation?

Researchers put 29 healthy adults (17 women, 9 vegetarians, ages 20–40) through a rigorous double-blind, placebo-controlled crossover design — the gold standard for supplement research. Each person was tested twice, a week apart, staying awake for 21 hours straight under close supervision. On one night they got a single oral dose of 0.2 g/kg creatine monohydrate (about 14 g for an average adult) at 9 pm; on the other, an identical-tasting placebo (resistant dextrin). Neither participants nor staff knew which was which. Cognitive tests — logic puzzles, memory tasks, reaction-time tests (PVT), and more — were run at baseline (6:30 pm) and again at midnight, 2:30 am, and 4:30 am.

The headline finding: sleep deprivation clobbered performance under placebo — reaction times slowed by over 13% and memory scores dropped by up to 24% by 4 am. Creatine blunted that decline. Averaged across the three overnight testing points, creatine-treated participants scored about 6% better on logic and numeric tasks, up to 12% faster on language processing, and showed less variability in reaction times compared to placebo — improvements of roughly 6-12% relative to the sugar pill.

Here's the catch, and it's an important one: this is a lower dose than the same research group tested previously (0.35 g/kg), and the effects were noticeably weaker this time around. The earlier high-dose study found stronger benefits, especially for memory and processing speed. That pattern suggests a dose-response relationship — more creatine reaching the brain during the acute stress of sleep deprivation may mean a bigger cognitive boost, up to a point.

Also notable: women showed substantially larger benefits than men, particularly in logic tasks (a striking 12.3% improvement, versus roughly 6% in the pooled/male-influenced group) and vigilance/reaction time. Vegetarians — who typically have lower baseline creatine stores from diet — also showed distinct benefits in processing speed and working memory. Nobody in the trial reported GI upset or other side effects; all 29 participants completed both sessions.

Sources: NutraIngredients coverage, MDPI/Nutrients full text, PubMed, prior high-dose study in Scientific Reports

What This Means For You

This isn't a green light to swap creatine for sleep — but it does suggest a low-risk, low-cost backup plan for situations where sleep loss is unavoidable (shift work, new parents, exam cramming, red-eye travel, on-call medical/military duty).

Dosage and timing: The tested dose — 0.2 g/kg body weight — works out to about 12–16 g for most adults, taken as a single dose roughly 3+ hours before you need peak alertness (it was given at 9 pm, with benefits showing from midnight onward). That's well above the typical 3–5 g daily "maintenance" dose sold in most tubs of creatine monohydrate, but still within the safety margins established by sports-nutrition research — the International Society of Sports Nutrition considers doses up to 0.3 g/kg/day (loading-phase levels) safe for healthy adults. Don't assume your usual scoop will replicate this effect; you'd need to measure out a much larger single dose.

What to buy: Stick with plain creatine monohydrate — the form used here (and in the vast majority of clinical research) — rather than pricier "advanced" formulations (HCl, buffered, etc.) that lack comparable evidence.

Who might benefit most: The data hints that women and vegetarians/vegans — groups that tend to have lower baseline creatine stores — may see proportionally larger cognitive benefits. If you're already creatine-naive and in one of these groups, an occasional acute dose before a known sleep-deprived stretch might be worth discussing with a doctor or dietitian.

Realistic expectations: Even in the best-responding subgroups, gains topped out around 12% relative to placebo — a real but modest cushion, not a caffeine-like jolt. Creatine did not prevent fatigue from climbing (sleepiness and fatigue scores rose almost identically in both groups) — it appears to protect specific cognitive functions rather than how sleepy you feel.

Important Considerations

This was a small (n=29), single-dose, acute-use study in healthy 20–40-year-olds — not people with chronic sleep disorders, older adults, athletes in training, or anyone with kidney issues (a common concern raised, though not tested here, with creatine). Results may not generalize beyond this narrow population.

Statistically, this study is messier than the topline "12% improvement" headline suggests. Of the many outcomes tested, most pooled (all-subjects) results were only marginally significant (p-values around 0.02–0.04) and did not survive the study's own Bonferroni correction for multiple comparisons — a standard adjustment to avoid false positives when testing many outcomes at once. Only the female-subgroup logic-task result held up under that stricter threshold. That means several of the more exciting findings (especially subgroup results in vegetarians and males) should be read as preliminary/exploratory rather than confirmed.

The trial also received a low Jadad quality score (1 out of 5) in the extraction data, largely because the paper didn't fully describe its randomization sequence-generation method or blinding procedures in enough detail to verify robustness — even though it was double-blind and placebo-controlled in design.

Other gaps: no brain creatine measurements were taken (so we don't actually know how much reached the brain at this dose vs. the higher dose used previously), total calorie intake wasn't controlled, and the study was funded entirely by a public research institute with no industry money — a plus for independence, but it's also only one study. Be skeptical of any supplement marketing that cites this single trial as proof creatine "boosts brainpower" broadly; the effect here was specific to acute sleep deprivation, not general cognitive enhancement in well-rested people. If you have kidney disease, are pregnant, or take medications, talk to a healthcare provider before taking a loading-level dose of any supplement.

Terms Explained

Creatine monohydrateThe most-studied form of creatine supplement, made of the compound creatine bound to a water molecule; used to support energy production in muscle and brain cells.

Crossover designA study structure where every participant receives both the treatment and the placebo (in random order, with a washout period between), so each person acts as their own control.

Double-blind, placebo-controlledNeither participants nor researchers know who received the real treatment versus an inactive look-alike substance, reducing bias in reported results.

Psychomotor Vigilance Test (PVT)A standard lab test measuring how quickly someone reacts to a simple visual cue, widely used to detect sleep-deprivation-related attention lapses.

Bonferroni correctionA statistical adjustment that raises the bar for 'significance' when many outcomes are tested at once, to avoid mistaking random noise for a real effect.

Dose-dependent effectWhen a bigger dose produces a bigger (or different) effect than a smaller dose — here, the higher 0.35 g/kg dose from a prior study showed stronger cognitive benefits than the 0.2 g/kg dose tested in this trial.

Loading phaseA short period (often 5-7 days) of taking a higher daily creatine dose (roughly 0.3 g/kg) to saturate the body's stores faster, typically followed by a lower daily maintenance dose.

Jadad scoreA 0-5 scale rating a clinical trial's reported quality based on randomization, blinding, and handling of dropouts; higher scores indicate more transparently rigorous reporting.

Technical Study Details

Study Design

RegistrationGerman Clinical Trials Register (DRKS): DRKS00039845

Total Score

JADAD Quality Assessment

/ 5

評価詳細

Randomization

0 / 2

Is the study described as randomized?

Yes+1

Rationale: The article explicitly and repeatedly describes the study as "randomized" — in the Figure 1 caption, the Methods (Experimental Procedure) section, and the Discussion section, using phrases such as "double-blind, randomized, cross-over design," "double-blind, randomized, prospective trial," "randomized, balanced order," and "randomized, controlled, double-blind, crossover study."

Is the method of randomization described and appropriate?

No-1

Rationale: The article states the study was randomized and describes a balanced crossover design with treatment order arranged in "pair-wise randomized, balanced order" by an external pharmacy. However, the actual method used to generate the randomization sequence (e.g., computer-generated random numbers, random number table) is not specified anywhere in the text. Since the specific randomization technique is not described, this does not meet the Jadad criteria for an appropriate, described method (per the scale, unspecified/undescribed randomization method should be scored as inappropriate/not described).

Blinding

0 / 2

Is the study described as double-blind?

Yes+1

Rationale: The article explicitly and repeatedly describes the study as "double-blind" — in the Figure 1 caption, in the Methods section (2.2 Experimental Procedure), and in the Discussion section, satisfying the criterion for a "yes" answer.

Is the method of blinding described and appropriate?

No-1

Rationale: The study is described as "double-blind" and states that verum and placebo were "prepared, blinded, and arranged in pair-wise randomized, balanced order" by an independent pharmacy, which indicates some blinding procedure was used. However, the article never describes the actual method used to make creatine monohydrate and the placebo (resistant dextrin) indistinguishable to participants and investigators — there is no mention of identical appearance, taste, smell, packaging, or encapsulation ensuring the two substances (which are chemically very different powders) could not be distinguished. Without this detail, the appropriateness of the blinding method cannot be verified, so per Jadad criteria this should be scored as not adequately described/appropriate.

Dropouts/Withdrawals

1 / 1

Is there a description of dropouts and withdrawals?

Yes+1

Rationale: The article explicitly states that all 29 enrolled participants completed the study ("All 29 participants successfully completed the study"), which directly addresses withdrawals/dropouts by confirming there were none. It also transparently reports the two minor instances of missing/excluded data points (one SPAN score not recorded, one PVT score removed as an outlier), specifying the number and reason. This satisfies the Jadad criterion of describing withdrawals/dropouts, since explicitly stating full completion (zero withdrawals) with the number of participants at the start and end is sufficient to score "yes."

Study Population

Sample Size29

Age Range20-40 years

ConditionSleep deprivation (healthy subjects), acute total sleep deprivation protocol (21 h)

Inclusion Criteria

Healthy subjects
No sleep disorders
Required to sleep at least 7 hours nightly for 2 weeks prior to and between measurement nights

Interventions

Creatine monohydrate (Creavitalis, micronized)

Treatment

Dose0.2 g/kg body weight (mean administered dose 14.1 ± 3 g)

Frequencysingle dose

Durationsingle administration

Routeoral

Placebo (Resistant Dextrin)

Control

Dose0.2 g/kg body weight

Frequencysingle dose

Durationsingle administration

Routeoral

Outcomes

Outcome	Type	Effect	p-value
Logic task score	Primary	6.10	p85 = 0.005Significant
Logic task processing speed	Secondary	10.30	p49 = 0.03Significant
Numeric ability task score	Secondary	6.20	p85 = 0.04Significant
Language task processing speed	Secondary	12.30	p85 = 0.04Significant
Forward digit span (SPAN)	Secondary	-	p85 = 0.0003Significant
Word Memory Test (WMT)	Secondary	-	p27 = 0.001Significant
Spatial N-back (2-back)	Secondary	10.80	p25 = 0.02Significant
PVT Mean Reaction Time	Primary	4.30	p49 = 0.01Significant
PVT Median Reaction Time	Primary	3.90	p49 = 0.02Significant
PVT Reaction Time Dispersion (RTD)	Primary	9.20	p85 = 0.02Significant
PVT Speed (inverse reaction time)	Primary	3.20	p49 = 0.02Significant
PVT Slowest 10% Mean Reaction Time	Secondary	10.60	p49 = 0.04Significant
Karolinska Sleepiness Scale (KSS)	Secondary	-	p27 = 1.5 × 10−15Significant
Fatigue Scale (FAT)	Secondary	-	p27 = 2.6 × 10−10Significant

Safety

Adverse Events0

Serious AEs0

Dropout Rate0.0%

Creatine supplementation was well tolerated, with no reports of gastrointestinal distress or other adverse physical symptoms. All 29 participants successfully completed the study.

Conclusion

A single acute dose of 0.2 g/kg creatine monohydrate mitigated, to a modest extent, sleep deprivation-induced deterioration in cognitive performance, with improvements of up to 12% in logic, numerical ability, language processing speed, and Psychomotor Vigilance Test performance compared to placebo. Females showed a more pronounced benefit than males, particularly in logic tasks, PVT, and processing speed. The effect was less pronounced than previously observed with a high dose (0.35 g/kg), suggesting a dose-dependent relationship between creatine availability and cerebral cellular uptake/cognitive benefit during sleep deprivation. The 0.2 g/kg dose was safe and well tolerated.

Limitations

Total caloric intake was not strictly controlled (only meat-free meals were restricted), which may have influenced performance in some tasks
Overall sample size (n=29) remains relatively small despite being larger than the previous study
No direct measures of brain creatine levels were obtained
No statistical correlation analyses with brain metabolic measures were conducted, limiting quantitative interpretation and direct comparison with the previous high-dose study
Sample consisted exclusively of young adults (20-40 years), limiting generalizability to older populations
Direct comparison with the previous high-dose (0.35 g/kg) study is not statistically possible due to differing study measurements